Strategies for improving treatment retention for buprenorphine/naloxone for opioid use disorder: a qualitative study of issues and recommendations from prescribers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Strategies for improving treatment retention for buprenorphine/naloxone for opioid use disorder: a qualitative study of issues and recommendations from prescribers ; volume:19 ; number:1 ; day:21 ; month:11 ; year:2024 ; pages:1-8 ; date:12.2024
Addiction science & clinical practice ; 19, Heft 1 (21.11.2024), 1-8, 12.2024
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13722-024-00516-z
- URN
-
urn:nbn:de:101:1-2502072103121.883628352628
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 2025-08-15T07:20:06+0200
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Young, Gary J.
- Young, Leonard D.
- Noor-E-Alam, Md
- SpringerLink (Online service)
Ähnliche Objekte (12)
Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series
Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial
Buprenorphine – The ideal drug for most clinical indications for an opioid?
Single high-dose buprenorphine for opioid craving during withdrawal
Safety and effectiveness of Buprenorphine-Naloxone sublingual tablet in the treatment of opioid use disorder
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial
Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series
Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial
Buprenorphine – The ideal drug for most clinical indications for an opioid?
Single high-dose buprenorphine for opioid craving during withdrawal
Safety and effectiveness of Buprenorphine-Naloxone sublingual tablet in the treatment of opioid use disorder
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial
Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series
Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial
Buprenorphine – The ideal drug for most clinical indications for an opioid?
Single high-dose buprenorphine for opioid craving during withdrawal
Safety and effectiveness of Buprenorphine-Naloxone sublingual tablet in the treatment of opioid use disorder
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)